[C:1]([C@:3]1([OH:23])[CH2:8][CH2:7][C@H:6]2[C@H:9]3[C:19](=[CH:20][CH2:21][C@:4]12[CH3:5])[C@:17]1([CH3:18])[C:12](=[CH:13][C:14](=[O:22])[CH2:15][CH2:16]1)[CH2:11][CH2:10]3)#[CH:2].CC(C)([O-])C.[K+].[Al]>>[C:1]([C@@:3]1([OH:23])[CH2:8][CH2:7][C@H:6]2[C@H:9]3[C:19](=[CH:20][CH2:21][C@:4]12[CH3:5])[C@:17]1([CH3:18])[C:12](=[CH:13][C:14](=[O:22])[CH2:15][CH2:16]1)[CH2:11][CH2:10]3)#[CH:2]17α-Ethynyl-17β-hydroxyandrosta-4,9(11)-dien-3-one (III A, (.S. Pat. No. 3,441,559, 0.3 g) and potassium t-butoxide (0.119 g) are combined in a vial which is then sealed with a septum and aluminum cap. The vial air-space is evacuated under reduced pressure, ethylene diamine (5 ml) is then added by a syringe followed by acetylene gas purge into the vapor space. The mixture is stirred at 20°-25° for 48 hours at which time TLC (ethyl acetate/hexane:50/50) indicates the title compound is obtained.